Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

ABEO ·

Abeona Therapeutics Inc. (ABEO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Abeona Therapeutics Inc. in 2026. The next earnings report is expected on November 16, 2026.

Earnings calendar

Next earnings date

16 Nov 2026

In 88 days

EPS estimate

-0.14

Revenue estimate

20.2M

Past earnings

13 Aug 2026
EPS actual
-0.35 (-51.1%)
estimate -0.23
Revenue actual
11.4M (-7.0%)
estimate 12.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 May 2026
EPS actual
-0.30 (+10.4%)
estimate -0.34
Revenue actual
8.7M (+90.7%)
estimate 4.6M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
17 Mar 2026
EPS actual
-0.36 (-2.3%)
estimate -0.35
Revenue actual
5.4M (+22.0%)
estimate 4.4M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.10 (+64.5%)
estimate -0.28
Revenue actual
0 (-100.0%)
estimate 5.2M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Abeona Therapeutics Inc. missed consensus estimates in its latest earnings, with EPS of -$0.35 versus an estimate of -$0.2317 and revenue of $11.38 million missing estimates by 7.0%. In the prior quarter both EPS and revenue came in ahead of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Vishwas Seshadri
Employees
226
IPO date
29 Jan 2018
ISIN
US00289Y2063
Website
abeonatherapeutics.com

Frequently asked questions

When does Abeona Therapeutics Inc. (ABEO) next report earnings?

Abeona Therapeutics Inc. (ABEO) is scheduled to report earnings on November 16, 2026.

What was Abeona Therapeutics Inc.'s most recent earnings date?

Abeona Therapeutics Inc. (ABEO) last reported earnings on August 13, 2026.

Where is Abeona Therapeutics Inc. stock listed?

Abeona Therapeutics Inc. (ABEO) is listed on Nasdaq.